Results 151 to 160 of about 1,518 (207)

Efficacy and Safety of Ruxolitinib Cream by Anatomic Region in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3

Dareen Siri, Amy S. Paller, April W. Armstrong, Linda Stein Gold, Howard Kallender, Daniel Sturm, Haobo Ren, Lawrence F. Eichenfield   +7 more
openalex   +2 more sources

Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to <12 Years: Results from a Phase 3 Double-Blind Vehicle-Controlled Study [PDF]

Weily Soong, Andrea L. Zaenglein, Megha M. Tollefson, Eric L. Simpson, Alim R Devani, Joel C. Joyce, Douglass W. Forsha, Joel Schlessinger, Howard Kallender, Brett Angel, Qian Li, Amy S. Paller   +11 more
openalex   +1 more source

Clinical Improvement of Necrobiosis Lipoidica Diabeticorum with Opzelura (Ruxolitinib) Cream: A Case Report

Annie Vu, Cheldon Ann Alcantara, Diem Q. Pham   +2 more
openalex   +2 more sources

Ruxolitinib cream demonstrated rapid reductions in itch and atopic dermatitis signs that correlated with biomarkers

Robert Bissonnette, Étienne Saint‐Cyr Proulx, Joel Corrêa da Rosa, Yeriel Estrada, Haobo Ren, Haq Nawaz, Philippa Halden, Diana Stefani-Hunyady, Katarina Popović, Angelina Volkova, Susan Smith, Emma Guttman‐Yassky   +11 more
openalex   +1 more source

Real-World Patient Experience With Ruxolitinib Cream in Vitiligo

SKIN The Journal of Cutaneous Medicine
Swapna Ambati, Dan Sturm, Chris O’Brien, Beth Schneider   +3 more
openaire   +1 more source

LB935 Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of ten patients [PDF]

Anna M. Bender, Jasmine Kaur, Nicole Babkowski, C.T. Richardson   +3 more
openalex   +1 more source

Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. [PDF]

Am J Clin Dermatol
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS.   +12 more
europepmc   +1 more source

Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Transplantation and Cellular Therapy
Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Veronica Rotemberg, Jelena Ostojic, Rizi Ai, Tara Maier, Mario E. Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew C. Harris, Doris M. Ponce   +14 more
openaire   +1 more source

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study

Lawrence F. Eichenfield, Linda Stein Gold, Eric L. Simpson, Andrea L. Zaenglein, April W. Armstrong, Megha M. Tollefson, Weily Soong, Lara Wine Lee, Alim R Devani, Seth Forman, Dareen Siri, Howard Kallender, Brett Angel, Qian Li, Xuejun Chen, Amy S. Paller   +15 more
openalex   +1 more source

Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety Review. [PDF]

Int J Mol Sci
Böll SL, Seyed Jafari SM, Conrad C, Schlapbach C.   +3 more
europepmc   +1 more source